ArriVent BioPharma Inc.
AVBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.41B
Close$
$1.18
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.41 Billion |
|---|---|
| Enterprise Value | $1.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.32 |
| Beta | 1.37 |
| Outstanding Shares | 47,606,857 |
Return
| Return on Equity | -44.63% |
|---|---|
| Return on Assets | -41.48% |
| Return on Invested Capital | -35.70% |
Valuation & Multiples
| P/E Ratio | -8.2 |
|---|---|
| PEG | -13.92 |
| Price to Sales | - |
| Price to Book Ratio | 4.36 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.55 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.95
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
$800,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0384▼ 26.19% |
|---|---|
| Total Calls | 911,400▲ 162.12% |
| Total Puts | 35,000▼ 66.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.02%▼ 4.69% |
|---|---|
| Total Invested | $1.64B▲ 68.53% |
| Investors Holding | 166▲ 21.00% |
ESG Score
No data